MTOR and neoplasm: VLX600 shows a significant reduction in tumour cell mitochondrial metabolism, which together with dichloroacetate (DCA), a clinically available glycolytic inhibitor, has proved to be an effective therapy against HNSCC in murine models, since the VLX600–DCA combination dramatically attenuates tumour cell metabolism and mTOR signaling [122,123].